RESEARCH TRIANGLE PARK, N.C. – August 31, 2011 – Quintiles today announced that Oren Cohen, M.D., will serve as Senior Vice President and Global Head of its Phase I Clinical Research division, which includes world-class facilities in Overland Park, Kansas (U.S.), London (U.K.) and Hyderabad (India). Cohen will leverage Quintiles’ breadth of clinical trial services and deep expertise in biomarker development to provide sponsors with an integrated early clinical development platform that reduces overall study costs, simplifies trial management and accelerates development, while ensuring quality and patient safety.
“Oren brings a deep understanding of the patient and a wealth of clinical and scientific expertise from his tenure as Quintiles’ Chief Medical and Scientific Officer (CMSO),” said Paula Brown Stafford, President of Quintiles Clinical Development. “Under Oren’s leadership, Quintiles will effectively help our customers navigate the New Health through a seamlessly integrated early clinical development offering that is world-class, both in terms of infrastructure and intellectual capital.”
Cohen received his M.D. from Duke University School of Medicine, and completed his internship and residency in internal medicine at The New York Hospital – Cornell Medical Center. He completed a fellowship in infectious diseases at the National Institute of Allergy and Infectious Diseases (NIAID), and then held several scientific and administrative positions within NIAID. Cohen joined Quintiles as a medical advisor in 2001 and was appointed CMSO in 2004. He is Consulting Professor of Medicine at Duke University Medical Center and is a Fellow of the Infectious Diseases Society of America.
“The Phase I clinical research space is changing rapidly, with fewer new molecules entering development and a fundamental shift in target study populations from healthy volunteers to patient groups,” said Cohen. “Biopharma companies are looking for an ally to help them manage these complexities, ensure patient safety and reduce costs, and Quintiles offers best-in-class early clinical development solutions to meet our customers’ needs.”
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.